London, UK (PRWEB) May 19, 2015
Over the last few decades, investigators have developed a number of methods to treat multiple myeloma. With surgery and radiation therapy being equally ineffective and not viable for the majority of cancer cases, chemotherapy has been often used in treating multiple myeloma. However, the latter treatment type exhibits modest pharmacological efficacy, which necessitates the discovery of better treatment options with reduced side effects and the potential to increase average survival rates. A number of innovative multiple myeloma therapeutic agents are available in the market, offering higher efficacy and safety levels. Forecasts suggest innovative therapeutics will provide better pharmacological benefit to patients and generate significant revenues moving forward.
Monoclonal antibodies (mAbs) have been usefully used for a number of malignancies owing to their high specificity and superior therapeutic effectiveness. The ability of targeted mAbs to bind to specific cells plays key part in minimising side effects of cancer treatment. Currently, researchers are developing targeted mAbs for the treatment of multiple myeloma, which are expected to offer better therapeutic effects. Novel cancer treatment modalities such as vaccination are also under study for exploring their pharmacological efficacy. Vaccines for treating multiple myeloma are likely to overcome relapse by activating cancer patients’ immune system; they are presently under various stages of development and reliable clinical findings are required for them to receive FDA marketing approval.
New report “Global Multiple Myeloma Drug Market & Pipeline Insight 2015” developed by Kuick Research is now available at MarketPublishers.com.
Title: Global Multiple Myeloma Drug Market & Pipeline Insight 2015
Published: May, 2015
Price: US$ 1,800.00
The report offers an unrivalled guide to the worldwide multiple myeloma drug universe. It provides a deep overview of the disease and reviews the mechanism of drugs for treating multiple myeloma. The study presents a deep investigation of the current state of the market and presents a shrewd look at the clinical pipeline; analyses the market dynamics covering key market drivers and challenges for commercialization of the respective drugs; provides a detail outlook for the market with in-depth forecasts. The report explores the multiple myeloma drug development pipeline, on the basis of indication, stage and company; as well as reviews the drugs available in the market; suspended and discontinued multiple myeloma drugs in clinical pipeline. The competitive landscape is also analysed including profiles of the top 15 market players.
Companies mentioned: Altor BioScience, AbbVie, Vaxil Biotherapeutics, Millennium Pharmaceuticals, Pfizer, Onyx Pharmaceuticals, Novartis, Genmab, Cleave Biosciences, Celegen Pharmaceuticals, Bristol-Myers Squibb, Biogen Idec, Benovus Bio, Astex Pharmaceuticals, and Astellas Pharma.
- In-depth study of the global market for multiple myeloma drugs.
- Review of market dynamics, including key growth drivers and challenges.
- Future outlook for the market including forecasts.
- Thorough evaluation of the multiple myeloma drug pipeline by indication, stage, and company.
- Overview of the 164 multiple myeloma drugs in development.
- Shrewd look at the 40 multiple myeloma drugs in phase II.
- Comprehensive analysis of the 9 marketed multiple myeloma drugs.
- Detailed insights into the competitive scene alongside the 15 leading players.
More new reports by the publisher can be found at Kuick Research page.